Clinical trials: Hypertensive Patients
Hypertension
Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults
The purpose of this study is to compare the blood pressure lowering efficacy of valsartan/hydrochlorothiazide (HCTZ) compared to hydrochlorothiazide for the treatment of obese hypertensive (mean sitting systolic blood pressure…
- Trial name
- NCT00439738
- Testing
- HCTZ + Amlodipine, Valsartan/HCTZ
- Where
- 5 sites in United States
- Volunteers
- 412 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Abdominal Obesity
Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension
Part 1 determined: aliskiren, amlodipine and angiotensin II concentrations in interstitial fluid of fat and skeletal muscle; aliskiren and angiotensin II concentrations, and renin activity and concentration in fat and skeletal…
- Trial name
- NCT00498433
- Testing
- Aliskiren, Amlodipine
- Where
- 2 sites in Germany
- Volunteers
- 46 people
- Sponsor
- Novartis
Glaucoma
Efficacy and Safety Assessment of T2345 in Ocular Hypertensive or Glaucomatous Patients
The purpose of this study is to assess the efficacy and safety of T2345 versus active comparator.
- Trial name
- NCT01156012
- Testing
- T2345, Prostaglandin
- Where
- France
- Volunteers
- 404 people
- Sponsor
- Laboratoires Thea
Hypertension
Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure
Randomized, double-blind, parallel group, multicenter study of subjects with Stage 1 or 2 essential hypertension who are not at target blood pressure (<140/90mmHg) at Baseline.
- Trial name
- NCT00624065
- Testing
- carvedilol controlled release/lisinopril
- Where
- 76 sites in United States
- Volunteers
- 348 people
- Sponsor
- GlaxoSmithKline
Hypertension
Effectiveness and Tolerability of Tarka® in the Treatment of Hypertensive Patients With High Risk of Developing Diabetes Mellitus
The aim of this post-marketing observational study (PMOS) is to provide data on the effectiveness and tolerability of Tarka in patients with a high risk of developing diabetes mellitus, as prescribed by the physicians in a…
- Trial name
- TARDIA (NCT01079195)
- Where
- 898 sites in Bulgaria, Czechia and 5 more
- Volunteers
- 15,436 people
- Sponsor
- Abbott
Hypertension in Pregnancy, Preeclampsia
Response to Anti-hypertensives in Pregnant and Postpartum Patients
In this study, the investigators will evaluate the blood pressure response to nifedipine and labetalol in pregnant and postpartum patients, who present with hypertensive disease in pregnancy with severe range blood pressure…
- Trial name
- NCT03506724
- Testing
- Nifedipine, Labetalol
- Where
- 2 sites in United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Hypertension
52-104 Week Off-therapy Second Extension to Study CSPP100A2365
52-104 week off-therapy second extension to study CSPP100A2365 to assess growth and development in pediatric hypertensive patients previously treated with aliskiren in studies SPP100A2365 and SPP100A2365E1
- Trial name
- NCT01420068
- Testing
- SPP100
- Where
- 25 sites in United States, Guatemala and 5 more
- Volunteers
- 106 people
- Sponsor
- LXO Group
Hypertension, Blood Pressure
Effect of Smart Phone Based Telemonitoring on Blood Pressure Among Hypertensive Patients in Primary Care
To test the hypothesis that hypertensive patients who participate in smart phone based telemonitoring of BP will conduct more home blood pressure monitoring, better self management behavior and greater reduction in blood pressure…
- Trial name
- NCT02046993
- Testing
- Smart phone telemonitoring HBP + enhanced usual care, Enhanced usual care
- Where
- Hong Kong
- Volunteers
- 210 people
- Sponsor
- Kwong Wah Hospital
Hypertension, Coronary Artery Disease
The Effect of Nebivolol in Hypertensive Patients With Coronary Artery Disease
This study is being done to see if the blood pressure lowering effect of an approved drug nebivolol is comparable to that of another approved drug carvedilol for the treatment of hypertension in patients who have coronary artery…
- Trial name
- NCT00673075
- Testing
- Nebivolol, Carvedilol
- Where
- 34 sites in United States
- Volunteers
- 39 people
- Sponsor
- Forest Laboratories
Essential Hypertension
Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients
This prospective multicenter, double blind study will evaluate the efficacy and safety of aliskiren versus ramipril in patients with moderate systolic essential hypertension.
- Trial name
- ALIAS (NCT01042392)
- Testing
- Aliskiren, Ramipril
- Where
- 98 sites in France
- Volunteers
- 506 people
- Sponsor
- Novartis
Hypertension
An Active-controlled, Clinical Trial to Assess Central Hemodynamic Effects of Bisoprolol in Hypertensive Patients (Central Hemodynamic Assessment Measured in Patient With HypertensION [CHAMPION])
Antihypertensive drugs aim to reduce blood pressure (BP) either through decrease of the total peripheral resistance through vasodilatation at the level of arterioles (microcirculation) or by decreasing the cardiac output through…
- Trial name
- NCT01079962
- Testing
- Bisoprolol, Atenolol
- Where
- South Korea
- Volunteers
- 209 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Ocular Hypertension, Glaucoma
Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients
The purpose of this study is to assess the efficacy and safety of T4032 versus Lumigan.
- Trial name
- NCT03825380
- Testing
- Bimatoprost, Lumigan®
- Where
- Estonia
- Volunteers
- 485 people
- Sponsor
- Laboratoires Thea
Hypertension
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
This double-blind 8 week study will evaluate dose response, efficacy (blood pressure lowering effect) and safety of aliskiren in children 6 - 17 years old with hypertension at low, mid and high weight-based doses.
- Trial name
- NCT01150357
- Testing
- Aliskiren (6.25/12.5/25 mg), Aliskiren (37.5/75/150 mg), Aliskiren (150/300/600 mg)
- Where
- 48 sites in United States, Belgium and 7 more
- Volunteers
- 267 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
A Study of the Effect of MK-8457 on Blood Pressure in Hypertensive Participants (MK-8457-004-AM1)
This study will evaluate the effect of treatment with multiple doses of MK-8457 on systolic blood pressure in participants with mild to moderate hypertension in addition to safety and tolerability.
- Trial name
- NCT01446003
- Testing
- MK-8457
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Merck Sharp & Dohme LLC
Essential Hypertension
Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine
This study will assess whether LCZ696 when used in combination with amlodipine will provide greater BP lowering benefit compared to amlodipine alone in Asian hypertensive patients not adequately responsive to amlodipine therapy.
- Trial name
- NCT01663233
- Testing
- LCZ696, Amlodipine
- Where
- 28 sites in China, Japan and 4 more
- Volunteers
- 266 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Effect of Carvedilol Controlled-Release (CR) and Atenolol on Central Blood Pressure
The purpose of this research study is to determine whether atenolol or controlled release carvedilol lower blood pressure in the body as effectively as in the arm.
- Trial name
- NCT00669279
- Testing
- Carvedilol CR, Atenolol
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Florida
Hypertension, Cardiovascular Diseases
Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients
The study is designed to evaluate the effect of treatment with Micardis/MicardisPlus on blood pressure and its ability to reduce different indicated cardiovascular risks.
- Trial name
- NCT00904371
- Where
- 36 sites in Slovenia
- Volunteers
- 211 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients
This study will assess blood pressure reduction with nebivolol or placebo in patients taking lisinopril or losartan.
- Trial name
- NCT00734630
- Testing
- nebivolol
- Where
- 75 sites in United States
- Volunteers
- 491 people
- Sponsor
- Forest Laboratories
Hypertension
Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension
This study will assess the safety and efficacy of aliskiren plus hydrochlorothiazide (HCTZ) in patients who do not achieve controlled blood pressure levels after treatment with another specified antihypertensive medication.
- Trial name
- AMAZING (NCT00867490)
- Testing
- Candesartan+HCTZ - Phase 1, Aliskiren+HCTZ - Phase 2, Aliskiren+HCTZ+amlodipine - Phase 3
- Where
- Germany
- Volunteers
- 186 people
- Sponsor
- Novartis
Non-diabetic Nephropathy With Hypertension
ARIA (Atacand Renoprotection In NephropAthy Pt.)
To determine the effective dose of candesartan cilexetil for reduction of urinary protein excretion in hypertensive patients with non-diabetic chronic kidney disease with baseline urinary protein/creatinine ratio between 500mg/g…
- Trial name
- PCR (NCT00573430)
- Testing
- Candesartan Cilexetil, Candesartan Cilexetil 32mg
- Where
- South Korea
- Volunteers
- 128 people
- Sponsor
- AstraZeneca